INFAB SYRUP

Indications

• Digestive disorders
• Bloating
• Flatulence
• Cramps
• Loss of appetite

Dosage

Children: Refer to established guidelines or a healthcare professional for specific dosing recommendations.

Adults: Refer to established guidelines or a healthcare professional for specific dosing recommendations.

Mechanism of action

The primary active compound in anise, anethole, exhibits various pharmacological effects. It has been shown to interact with GABA receptors, which may contribute to its sedative effects. Additionally, anethole possesses antispasmodic properties, which can help relieve gastrointestinal discomfort. The compound also exerts antimicrobial activity against certain pathogens, enhancing its role in digestive health.

Pharmacodynamics

Anisum has been utilized for its potential benefits in alleviating bloating, gas, and other digestive issues. Its anethole content may stimulate the secretion of digestive enzymes, promoting better digestion and absorption of nutrients. Furthermore, its antispasmodic effects can help reduce intestinal cramps and discomfort. The aromatic properties of anise may also contribute to its effects on appetite stimulation and overall gastrointestinal health.

Pharmacokinetics

The pharmacokinetics of anise, particularly its active ingredient anethole, involve absorption through the gastrointestinal tract after oral administration. Anethole is metabolized in the liver and is excreted primarily through urine. The half-life of anethole can vary, influenced by factors such as dosage and individual metabolic differences. The essential oils in anise are generally well-tolerated, though excessive consumption may lead to gastrointestinal disturbances.

Adverse effects

• Allergic reactions
• Gastrointestinal upset
• Nausea
• Vomiting

Interactions

• May interact with anticoagulants
• Potential interaction with antidiabetic medications

Precautions

• Use with caution in individuals with allergies to anise or related plants
• Monitor for potential allergic reactions
• Use cautiously in patients with hormone-sensitive conditions

Pregnancy

Anise is considered safe in food amounts during pregnancy, but high doses should be avoided due to potential hormonal effects.

Breast-feeding

Generally regarded as safe when consumed in food amounts, but high doses should be avoided.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Formulations

• Whole seeds
• Essential oil
• Tincture

Indications

• Digestive disorders
• Inflammation
• Wound healing
• Nutritional support
• Antioxidant support

Dosage

Children: Refer to established guidelines for dietary intake or consult a healthcare provider for specific therapeutic uses.

Adults: Refer to established guidelines for dietary intake or consult a healthcare provider for specific therapeutic uses.

Mechanism of action

Papain, the primary enzyme in carica, acts as a protease, facilitating the hydrolysis of peptide bonds in proteins. This enzymatic activity aids in digestion by breaking down proteins into more easily absorbed amino acids and peptides. Additionally, the antioxidants in carica may help reduce oxidative stress, thereby exhibiting anti-inflammatory effects.

Pharmacodynamics

The pharmacodynamic effects of carica largely stem from its enzymatic activity and antioxidant properties. Papain enhances protein digestion, improving nutrient absorption. The antioxidants present in carica, such as vitamin C, help neutralize free radicals, potentially reducing inflammation and promoting overall health. The anti-inflammatory effects may also be beneficial in managing conditions associated with inflammation.

Pharmacokinetics

The pharmacokinetics of carica are not well defined in clinical literature, as it is primarily consumed as a food source rather than a pharmaceutical product. However, the absorption of nutrients and enzymes from carica can vary based on the individual's digestive health. The bioavailability of papain may be influenced by factors such as gastric pH, presence of other food substances, and individual metabolic rates.

Pregnancy

There is insufficient reliable information regarding the safety of carica during pregnancy, so it is advisable to avoid use unless directed by a healthcare professional.

Breast-feeding

Due to a lack of adequate studies, the safety of carica during breastfeeding is not well established. Consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Anxiety
• Insomnia
• Gastrointestinal disturbances
• Muscle spasms
• Inflammatory conditions

Dosage

Children: Refer to herbal supplement guidelines, as specific dosing can vary widely based on preparation and individual response.

Adults: Refer to herbal supplement guidelines, as specific dosing can vary widely based on preparation and individual response.

Mechanism of action

The mechanism of action of chamomilla is primarily attributed to its active constituents, including flavonoids and terpenoids. These compounds exert their effects by modulating neurotransmitter activity, particularly enhancing the activity of gamma-aminobutyric acid (GABA). This results in a sedative effect, which can help mitigate anxiety and promote sleep. Additionally, chamomilla has been shown to have anti-inflammatory actions, which contribute to its efficacy in treating gastrointestinal spasms and discomfort.

Pharmacodynamics

Chamomilla exhibits a range of pharmacodynamic effects, including anxiolytic, sedative, anti-inflammatory, and antispasmodic properties. The sedative effects are primarily mediated through GABAergic pathways, promoting relaxation and reducing anxiety levels. Its anti-inflammatory effects help in alleviating pain and discomfort, particularly in conditions associated with muscle spasms and gastrointestinal disturbances.

Pharmacokinetics

The pharmacokinetics of chamomilla have not been extensively studied, but it is known that the bioactive compounds are absorbed in the gastrointestinal tract after ingestion. The onset of action varies depending on the form of administration (e.g., tea, extract), with effects typically observed within 30 minutes to an hour. The metabolites are likely excreted via urine, although specific half-life and clearance data are not well-documented.

Adverse effects

• Allergic reactions
• Drowsiness
• Nausea
• Vomiting
• Diarrhea

Interactions

• May potentiate the effects of sedatives
• May interact with anticoagulants

Precautions

• Use with caution in individuals with allergies to plants in the Asteraceae family
• Monitor for allergic reactions

Pregnancy

Chamomile is generally considered safe in pregnancy, but high doses should be avoided due to potential uterine stimulation.

Breast-feeding

Chamomile is likely safe during breastfeeding when consumed in moderation, but consult a healthcare provider for specific concerns.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Dried flowers
• Tea bags
• Liquid extracts
• Essential oil

Indications

• Secondary hyperparathyroidism in chronic kidney disease (CKD) patients on dialysis
• Hypercalcemia in patients with parathyroid carcinoma

Dosage

Adults: The initial dose of cinacalcet is usually 30 mg once daily, which may be titrated based on serum calcium levels, up to a maximum of 180 mg per day, given in divided doses.

Mechanism of action

Cinacalcet acts as a positive allosteric modulator of the calcium-sensing receptor, enhancing the receptor's sensitivity to extracellular calcium. This results in decreased release of parathyroid hormone (PTH), leading to lower serum calcium levels and decreased bone resorption.

Pharmacodynamics

The drug effectively lowers serum calcium and phosphate levels by inhibiting PTH secretion. The modulation of the calcium-sensing receptor leads to a reduction in bone turnover and calcium mobilization from bone, which is beneficial in conditions characterized by elevated PTH levels.

Pharmacokinetics

Cinacalcet is well absorbed after oral administration, with peak plasma concentrations typically occurring within 2-6 hours. It has a high protein binding rate (approximately 93%) and is extensively metabolized in the liver, primarily via CYP2D6, with a half-life of around 30-40 hours. The drug's clearance may be affected by hepatic function and CYP2D6 polymorphisms.

Interactions

• cinacalcet+galantamine: Moderate (increases exposure)
• cinacalcet+risperidone: Moderate (increases exposure)
• cinacalcet+atomoxetine: Moderate (increases exposure)
• cinacalcet+anticholinesterases, centrally acting: Moderate (increases exposure)
• cobicistat+cinacalcet: Moderate (increases exposure)
• cinacalcet+eliglustat: Moderate (increases exposure)
• cinacalcet+fesoterodine: Moderate (increases exposure)
• idelalisib+cinacalcet: Moderate (increases exposure)
• mitotane+cinacalcet: Moderate (decreases exposure)
• cinacalcet+pitolisant: Moderate (increases exposure)

Dosage

Children: Refer to specific drug guidelines as no specific dosing can be provided.

Adults: Refer to specific drug guidelines as no specific dosing can be provided.

Pregnancy

Consult relevant guidelines, as safety may vary depending on the specific drug mechanism and use.

Breast-feeding

Consult relevant guidelines, as safety may vary depending on the specific drug mechanism and use.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Fever
• Upper respiratory infections
• Inflammatory conditions
• Digestive disorders
• Hepatoprotection
• Viral infections

Dosage

Children: Dosing in children should be determined by a healthcare provider, considering the child's age

Adults: Recommended dosages of kalmegh vary based on the formulation used. It is important to refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

Kalmegh exerts its therapeutic effects primarily through the modulation of the immune system and the inhibition of pro-inflammatory cytokines. Andrographolide interacts with various signaling pathways, including the NF-κB pathway, leading to a decrease in inflammation and an increase in immune response. It also has hepatoprotective properties, which help to safeguard liver function against toxins and oxidative stress.

Pharmacodynamics

Kalmegh demonstrates a range of pharmacodynamic effects, including anti-inflammatory, analgesic, and immunostimulant activities. The herb has shown efficacy in reducing the severity and duration of upper respiratory tract infections and has been studied for its potential benefits in managing conditions such as dengue fever and hepatitis. The pharmacological actions are attributed to the presence of diterpenoid lactones, with andrographolide being the most significant compound.

Pharmacokinetics

The pharmacokinetics of kalmegh can vary based on the formulation and method of administration. After oral administration, the absorption of andrographolide is relatively low, with bioavailability affected by first-pass metabolism. The compound is metabolized in the liver and excreted mainly through the bile. The half-life of andrographolide is not well-defined, but its effects can be prolonged due to its interaction with various biological pathways. Further studies are needed to fully elucidate the pharmacokinetic profile.

Adverse effects

• Gastrointestinal disturbances
• Allergic reactions
• Headache
• Fatigue

Precautions

• Use with caution in patients with liver disorders
• Consider potential allergic reactions in sensitive individuals

Pregnancy

Limited data available, use with caution and consult a healthcare provider.

Breast-feeding

Limited data available, consult a healthcare provider before use.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Dried leaf powder
• Extracts
• Capsules

Indications

• Digestive disorders
• Inflammation
• Constipation
• Nutritional support
• Immune system support

Dosage

Children: Refer to established dietary guidelines or consult a healthcare professional for specific recommendations.

Adults: Refer to established dietary guidelines or consult a healthcare professional for specific recommendations.

Mechanism of action

The primary active components of papaya include papain and other proteolytic enzymes, which facilitate the digestion of proteins in the gastrointestinal tract. Papain acts by cleaving peptide bonds in proteins, leading to their breakdown into smaller peptides and amino acids. This enzymatic activity can aid in improving nutrient absorption and reducing symptoms of digestive discomfort.

Pharmacodynamics

Papaya exhibits anti-inflammatory and antioxidant properties, attributed to its high levels of vitamins A, C, and E, as well as flavonoids and carotenoids. These compounds help neutralize free radicals in the body, potentially reducing oxidative stress and inflammation. Additionally, papaya's enzymatic activity may help alleviate bloating and constipation, enhancing overall gastrointestinal health.

Pharmacokinetics

The bioavailability of papaya's active compounds varies depending on the preparation and method of consumption. When consumed as a whole fruit, the digestion and absorption of its components occur in the gastrointestinal tract. The enzymes like papain are generally stable in the acidic environment of the stomach, allowing for effective protein digestion. However, the precise pharmacokinetic parameters of papaya's components are not well-established in the literature.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Skin rashes

Interactions

• May interact with anticoagulants and antiplatelet drugs
• Potential interaction with certain antihypertensive medications

Precautions

• Use with caution in individuals with known allergies to papaya or related plants
• Caution in patients with diabetes due to potential effects on blood sugar levels

Pregnancy

Papaya is generally considered safe in moderate amounts, but unripe papaya should be avoided due to potential effects on uterine contractions.

Breast-feeding

Limited information is available, but small amounts of ripe papaya are likely safe during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Fresh fruit
• Dried fruit
• Papaya enzyme supplements

Indications

• Erectile dysfunction
• Pulmonary hypertension
• Heart failure
• Chronic obstructive pulmonary disease (COPD)

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines, as paediatric dosing can differ significantly from adult dosing.

Adults: Refer to the BNF for specific dosing information, as it varies depending on the particular phosphodiesterase type inhibitor and the condition being treated.

Mechanism of action

Phosphodiesterase type inhibitors work by blocking the degradation of cAMP and cGMP, which results in increased levels of these second messengers within cells. Elevated cAMP levels lead to smooth muscle relaxation, vasodilation, and increased myocardial contractility. Additionally, cGMP plays a critical role in vascular smooth muscle relaxation and platelet aggregation inhibition.

Pharmacodynamics

The pharmacodynamic effects of phosphodiesterase type inhibitors include enhanced vasodilation, improvement in myocardial oxygen supply, and reduced myocardial oxygen demand. This results in beneficial effects for patients with conditions such as heart failure, pulmonary hypertension, and certain forms of erectile dysfunction. The time to onset of action and duration of effect can vary depending on the specific agent within this class.

Pharmacokinetics

Phosphodiesterase type inhibitors are generally well absorbed after oral administration, with peak plasma concentrations typically achieved within 1 to 2 hours. The metabolism of these drugs primarily occurs in the liver via cytochrome P450 enzymes, leading to various metabolites. The elimination half-life varies between agents but is generally in the range of 4 to 12 hours, with renal excretion being a significant route of elimination for some compounds.

Interactions

• aminophylline+phosphodiesterasetype-: Severe (increases exposure)
• cobicistat+phosphodiesterasetype-: Severe (increases exposure)
• idelalisib+phosphodiesterasetype-: Severe (increases exposure)
• clarithromycin+phosphodiesterasetype-: Severe (increases exposure)
• mitotane+phosphodiesterasetype-: Severe (decreases exposure)
• nicorandil+phosphodiesterasetype-: Severe (increases risk of hypotension)
• tucatinib+phosphodiesterasetype-: Severe (increases exposure)
• ribociclib+phosphodiesterasetype-: Severe (increases exposure)
• rifampicin+phosphodiesterasetype-: Severe (decreases exposure)
• theophylline+phosphodiesterasetype-: Severe (increases exposure)